Abstract
Diabetes mellitus (DM) is associated with the development, progression and severity of periodontal disease. Since poorly controlled diabetic patients present impaired tissue healing and immuno-inflammatory response, the use of adjuvant therapies, such as host response modulators, may attend to specific therapeutic needs of this group of patients. The bisphosphonate tiludronic acid (TIL) p…